London, UK (PRWEB) August 22, 2014
The improved access to antiretroviral drugs and treatments in the recent past, specifically in the developing world, has led to the decline in the rate of HIV infection and the number of deaths due to AIDS globally. However, despite the fact that HIV infection rates are declining, the number of new patients becoming affected by the virus is on the rise. With all the conscious efforts being undertaken by all related organisations and stakeholders, by 2015, significant investments are expected to be recorded in this area with the WHO establishing a goal to treat nearly 15 million HIV patients.
The HIV infection drug market is likely to see increased competition amongst the multiple players, leading to the reduction of the overall cost of drugs in the long run. In addition, economies of scale are set to act as a key factor driving down the cost of drugs used to treat HIV-infected people, thus making the respective drugs and therapies more affordable.
In next 5 to 8 years, the pharma companies are likely to be focusing on the development of an effective vaccine to prevent this disease from spreading. With the progress of trials and gathering of information on the efficacy and safety of novel products, there is a pressing demand for strategising candidate pipelines and prioritising the decisions. The funds, which are limited in nature, need to be particularly channelised towards only those products and approaches which have high probability of being success.
New research report “Global HIV Infection Drug Market & Pipeline Insight” worked out by Kuick Research is now available at MarketPublishers.com.
Title: Global HIV Infection Drug Market & Pipeline Insight
Published: August, 2014
Price: US$ 2,400.00
The report provides a complete guide to the world HIV infection drug market, aiming at assisting various organisations in the clinical development of drugs for the treatment of this infection. The research study provides a comprehensive overview the market landscape and dynamics, discusses FDA’s regulatory framework for development of HIV vaccine, and also looks at EMA’s regulatory environment for the development of products used to treat HIV infection. The publication presents a deep overview of the worldwide HIV infection drug clinical pipeline (by phase, company and country), covers the marketed HIV drug clinical profile (by company and country), and reviews the suspended and discontinued HIV drugs in clinical trials (by company, phase and country). The extensive competitive landscape analysis with profiles of the leading players, as well as an in-depth patent analysis can be found in the report as well.
Companies mentioned: Antigen Express, FIT Biotech, Novartis, Bionor Pharma, Sanofi Pasteur, Gilead Sciences, GeoVax, Immune Response BioPharma, Inovio Pharmaceuticals, Glaxo Smithkline, and GenVec.
- Comprehensive overview on the global HIV infection drug market and incidence scenario.
- Insightful review of the FDA & EMA Regulation for development of the drugs targeted for HIV.
- All-round analysis of the world HIV infection drug clinical pipeline by phase, pharma company and nation.
- Profound insights into the worldwide HIV clinical pipeline, with coverage of 315 drugs in development phases.
- Keen look at the majority of HIV drugs in preclinical phase, covering 144 drugs.
- Comprehensive study of the 37 marketed HIV drugs.
- Profiles of the 539 suspended and discounted HIV drugs in clinical pipeline.
- Thorough scrutiny of the major patents, including patent number and technology.
More new studies by the publisher can be found at Kuick Research page.